Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6132735 | Journal of Virological Methods | 2016 | 5 Pages |
Abstract
Treatment of chronic hepatitis B virus (HBV) infection with lamivudine-monotherapy rapidly selects mutant variants in a high proportion of individuals. Monitoring lamivudine resistance by consensus sequencing is costly and insensitive for detection of minority variants. An oligonucleotide ligation assay (OLA) for HBV lamivudine-resistance was developed and compared to consensus sequencing. Both assays detected drug resistance mutations in 35/64 (54.7%) specimens evaluated, and OLA detected minority mutants in an additional six (9.4%). OLA may offer a sensitive and inexpensive alternative to consensus sequencing for detection of HBV drug resistance in resource-limited settings.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Ingrid A. Beck, Rachel Payant, Nicole Ngo-Giang-Huong, Woottichai Khamduang, Laddawan Laomanit, Gonzague Jourdain, Lisa M. Frenkel,